title: Administration of long-term estradiol and progesterone followed by progesterone withdrawal does not alter the plasma oxytocin secretory response to cholecystokinin or the pituitary oxytocin content in ovariectomized rats.
abstract: The hormone oxytocin (OT) is important for several pre- and postpartum events, including uterine contractions at parturition, the induction of maternal behavior, and milk ejection during nursing. During late pregnancy, OT mRNA is increased in the paraventricular nucleus (PVN) due to high estrogen and declining progesterone levels. Administration of sequential estrogen and progesterone to, followed by withdrawal of progesterone from, an ovariectomized rat also increases OT mRNA. However, pituitary OT peptide is not affected. In the present experiment, we determined if this steroid exposure alters peripheral OT secretion during a provocative stimulus to OT release, such as cholecystokinin (CCK). Adult ovariectomized Sprague-Dawley rats were implanted on day 1 with either estrogen or empty silastic capsules, on day 3 with progesterone or empty capsules, and on day 14 progesterone or empty capsules were removed. Forty-eight hrs after removal of the progesterone capsules, plasma OT was measured before and after i.v. injection of 10 micrograms/kg of CCK. At the completion of the study, pituitary glands were removed and OT peptide was measured. No significant differences were found between the sham and hormone-treated animals either in their basal or CCK-stimulated plasma OT levels or their pituitary content of OT peptide. Although sequential exposure to estradiol and progesterone followed by withdrawal of progesterone has been shown previously to increase PVN OT mRNA, neither pituitary OT immunoreactivity nor basal and CCK-stimulated release of plasma OT is affected by this treatment. Although the mechanism of this steroid effect is not yet understood, our observations suggest a unique action of gonadal steroids upon PVN OT neurons.
authors.affiliation: Department of Medicine, University of Pittsburgh School of Medicine, PA, USA. jamico+@pitt.edu
authors.forename: J A
authors.initials: JA
authors.lastname: Amico
authors.forename: A
authors.initials: A
authors.lastname: Thomas
authors.forename: D J
authors.initials: DJ
authors.lastname: Hollingshead
authors.forename: N B
authors.initials: NB
authors.lastname: Kim
mesh_terms: D000818:Animals; D002766:Cholecystokinin / Q000494:pharmacology*; D004353:Drug Evaluation, Preclinical; D004343:Drug Implants; D004958:Estradiol / Q000494:pharmacology*; D005260:Female; D010052:Ovariectomy; D010053:Ovary / Q000502:physiology; D010121:Oxytocin / Q000097:blood / Q000378:metabolism*; D010902:Pituitary Gland / Q000187:drug effects* / Q000378:metabolism; D011374:Progesterone / Q000009:adverse effects / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012636:Secretory Rate / Q000187:drug effects; D013375:Substance Withdrawal Syndrome; D013997:Time Factors
chemical_list: D004343:Drug Implants; D011374:Progesterone; D004958:Estradiol; D010121:Oxytocin; D002766:Cholecystokinin